N4 Pharma PLC (N4P) Rating Reiterated by Beaufort Securities

N4 Pharma PLC (LON:N4P)‘s stock had its “speculative buy” rating restated by equities research analysts at Beaufort Securities in a research report issued on Thursday.

Receive News & Ratings for N4 Pharma PLC Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for N4 Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.

N4 Pharma PLC (N4P) opened at 6.25 on Thursday. The company’s market capitalization is GBX 4.67 million. The firm has a 50-day moving average of GBX 8.52 and a 200-day moving average of GBX 6.54. N4 Pharma PLC has a 52 week low of GBX 1.20 and a 52 week high of GBX 12.50.

TRADEMARK VIOLATION NOTICE: “[[title]]” was reported by [[site]] and is the property of of [[site]]. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at [[permalink]].

N4 Pharma PLC Company Profile

N4 Pharma Plc, formerly Onzima Ventures plc, is a United Kingdom-based specialist pharmaceutical company. The Company is engaged in reformulating existing drugs and vaccines to improve their performance. It operates in two divisions: generic and vaccines. Its generics division includes Sildenafil, Sartans, Aprepitant and Single dose Hepatitis B.